Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089973
Status:
COMPLETED
Last Update Posted:
2018-02-26
First Post:
2004-08-18
Brief Title:
Study Of Ispinesib In Subjects With Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Phase II Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to find how breast cancer responds to the investigational drug Ispinesib An investigational drug is a drug that has not been approved by the Food and Drug Administration FDA and is available for research use only In particular this study will try is to find the answers to the following research questions
1 Does breast cancer respond to Ispinesib
2 What are the side effects of Ispinesib
3 How much Ispinesib is in the blood at specific times after it is taken
1 Does breast cancer respond to Ispinesib
2 What are the side effects of Ispinesib
3 How much Ispinesib is in the blood at specific times after it is taken
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None